Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/21/2007

rrently available drugs.

"Assessment of In Vitro Activity of Cethromycin Against Strains of Haemophilus Influenzae"

Cethromycin demonstrated potent in vitro activity against all Haemophius influenzae isolates studied regardless of beta-lactamase status. Based on the MIC data, cethromycin potency was comparable to telithromycin and azithromycin, and was superior to clarithromycin. These findings demonstrate that cethromycin has the potential to be a potent therapeutic option for the treatment of CAP caused by Haemophilus influenzae.

The following poster presentations demonstrated the potency of cethromycin as a potential treatment against bioterrorism pathogens:

"Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques"

All antibiotic treated animals maintained normal hematologic parameters and remained abacteremic throughout the treatment period. All cethromycin- treated animals survived, with only 1/10 demonstrating abnormal hematologic parameters following antibiotic cessation. One ciprofloxacin-treated animal demonstrated clinical signs of infection, bacteremia, alterations in hematologic and coagulation parameters, and died nine days after cessation of antibiotic treatments. All 10 control monkeys demonstrated a combination of clinical signs of anthrax, bacteremia, and/or alterations in hematologic and coagulation parameters post-challenge with five of ten succumbing to the infection. This study demonstrated that a thirty day course of oral cethromycin was 100% protective against a lethal dose of inhaled Bacillus anthracis Ames strain spores.

"Antimicrobial Activity of Cethromycin, a Novel Ketolide, Tested Against a Diverse Collection of Francisella Tularensis Strains"

Cethromycin was efficacious against 30 Francisella tularensis strains. Cethromycin had significant in vitro activity against Francisella tularensis. Cethromycin preferentially accumulates in the alveolar cells of the lungs,
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... Systems, Inc. (Nasdaq: DCTH ) announced that it ... recent corporate developments and update its progress on Monday, November ... Chief Executive Officer will host the call. ... domestic participants and 617-614-4927 for international participants, both using passcode ...
... 28, 2011 Mentor Foundation USA , the leading ... National Institute on Drug Abuse and The Embassy of Sweden ... together top scientists, parents, educators and community members to address ... The seminar will be held on Wednesday, Nov. 2 ...
Cached Medicine Technology:Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 2Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 3Escalating Trend of Prescription Drug Abuse Among Youth Seminar Hosted by Mentor Foundation USA 2
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... breast cancer cell proliferation in a randomized clinical trial, ... Research , a journal of the American Association for ... professor of surgery at the Robert H. Lurie Comprehensive ... this study are consistent with the findings of previous ...
... HealthDay Reporter , THURSDAY, Feb. 2 (HealthDay News) ... lower the risk of stroke, but a new study suggests ... of recovery if they do suffer a stroke. Researchers ... before a stroke responded much better to clot-busting drugs, had ...
... , In Europe, the number of seniors aged 70 ... 20 years, while those aged 80 and over will ... expect a corresponding increase in the number of people ... osteoporosis, arthritis, heart and lung diseases and dementia. The ...
... HealthDay Reporters , THURSDAY, Feb. 2 (HealthDay ... traveling from neuron to neuron in much the same way ... research with mice suggests. Scientists reported Thursday that ... in the brains of those with Alzheimer,s -- starts in ...
... be at higher risk of having a stroke than they ... Langone Medical Center and colleagues found that traditional risk factors ... as accurate at predicting risk in postmenopausal women as previously ... triglyceride levels to determine which women are at highest risk ...
... Feb. 2 (HealthDay News) -- Sometimes, there,s nothing better than ... where the itch resides is key to the pleasure ... itch and might even help folks battling itchy skin ailments, ... dermatology at Wake Forest Baptist Medical Center in Winston-Salem, N.C. ...
Cached Medicine News:Health News:Being Fit Before Stroke May Aid Recovery 2Health News:Being Fit Before Stroke May Aid Recovery 3Health News:New study to assess 3 simple, cost-effective strategies to promote healthy aging 2Health News:Mouse Study Suggests Alzheimer's Spreads Through Brain Like an Infection 2Health News:Mouse Study Suggests Alzheimer's Spreads Through Brain Like an Infection 3Health News:Triglyceride levels predict stroke risk in postmenopausal women 2Health News:Pleasure in Scratching an Itch May Depend on Location 2
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
... VH Fibrin Sealant has been shown to ... repair. Containing uniform, reproducible concentrations of fibrinogen ... the final stage of the coagulation cascade ... that firmly adheres to connective tissue like ...
... catheter provides maximum heat exchange power ... The Fortius catheter incorporates a proprietary ... the ultimate solution for endovascular cooling ... percutaneously into the femoral vein residing ...
...
Medicine Products: